AbCellera Biologics Inc. (ABCL) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, AbCellera Biologics reported revenue of $75.1M, up 160.6% from $28.8M the year before. Net income was -$146.4M (a -194.9% net margin), or -$0.49 per diluted share. Operating margin was -289.0%. Operating activities generated -$131.3M of cash, leaving -$174.1M of free cash flow. At fiscal year end, AbCellera Biologics held $1.36B in total assets against $390.0M in total liabilities, including $128.5M of cash and equivalents.
Open the full interactive AbCellera Biologics financials → Quarterly statements, key ratios, valuation history and price charts.
AbCellera Biologics Key Stats
| Share Price | $12.61 |
|---|---|
| Market Cap | $3.85B |
| Revenue YoY Growth | +160.6% |
| 52-Week Range | $2.78 – $14.82 |
| Shares Outstanding | 305.6 million (basic, 2026 Q2) |
AbCellera Biologics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $375.2M | $485.4M | $38.0M | $28.8M | $75.1M |
| Operating Income | $204.4M | $216.5M | -$237.2M | -$314.8M | -$217.1M |
| Pre-Tax Income | $219.1M | $239.1M | -$174.0M | -$200.4M | -$177.6M |
| Income Tax | $65.7M | $80.6M | -$27.6M | -$37.5M | -$31.2M |
| Net Income | $153.5M | $158.5M | -$146.4M | -$162.9M | -$146.4M |
| Diluted EPS | $0.48 | $0.50 | -$0.51 | -$0.55 | -$0.49 |
AbCellera Biologics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $9.0M | $44.9M | $8.3M | $4.0M |
| Net Income | -$57.1M | -$8.9M | -$43.2M | -$55.4M |
| Diluted EPS | -$0.19 | -$0.03 | -$0.14 | -$0.18 |
AbCellera Biologics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $476.1M | $386.5M | $133.3M | $156.3M | $128.5M |
| Current Assets | $929.8M | $1.03B | $872.0M | $751.4M | $728.2M |
| Total Assets | $1.32B | $1.54B | $1.49B | $1.36B | $1.36B |
| Current Liabilities | $120.7M | $118.3M | $119.0M | $76.6M | $64.3M |
| Total Liabilities | $292.8M | $307.6M | $335.8M | $304.5M | $390.0M |
| Shareholders' Equity | $1.03B | $1.23B | $1.15B | $1.06B | $966.9M |
AbCellera Biologics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | $244.6M | $277.4M | -$43.9M | -$108.6M | -$131.3M |
| Cash From Investing | -$332.2M | -$352.6M | -$221.1M | $121.4M | $87.8M |
| Cash From Financing | -$3.9M | -$1.6M | $10.4M | $12.8M | $14.1M |
| Free Cash Flow | $186.1M | $206.7M | -$120.8M | -$187.0M | -$174.1M |
Figures from AbCellera Biologics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full AbCellera Biologics financials page for every line item.
AbCellera Biologics Company Profile
| Ticker | ABCL |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Vancouver, British Columbia, Canada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001703057 |
Frequently Asked Questions
What was AbCellera Biologics' revenue in fiscal 2025?
AbCellera Biologics (ABCL) reported revenue of $75.1M for fiscal 2025.
What is AbCellera Biologics' annual revenue history?
AbCellera Biologics' annual revenue by fiscal year: 2021: $375.2M; 2022: $485.4M; 2023: $38.0M; 2024: $28.8M; 2025: $75.1M.
What was AbCellera Biologics' net income in fiscal 2025?
AbCellera Biologics reported net income of -$146.4M for fiscal 2025.
What was AbCellera Biologics' earnings per share (EPS) in fiscal 2025?
AbCellera Biologics' diluted EPS was -$0.49 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did AbCellera Biologics generate in fiscal 2025?
AbCellera Biologics generated -$174.1M of free cash flow in fiscal 2025.
What was AbCellera Biologics' revenue last quarter?
In its most recent reported quarter (2026 Q2), AbCellera Biologics reported revenue of $4.0M.
How many shares of AbCellera Biologics are outstanding?
AbCellera Biologics reported a weighted average of 305.6 million basic shares outstanding in 2026 Q2.
What is AbCellera Biologics' market cap?
Based on its latest closing price, AbCellera Biologics (ABCL) has a market capitalization of about $3.85B.
When does AbCellera Biologics' fiscal year end?
AbCellera Biologics' fiscal year end, as registered with the SEC, is December 31.
Where is AbCellera Biologics headquartered?
AbCellera Biologics lists its business address in Vancouver, British Columbia, Canada in its SEC filings.